We found that it reduced tumor growth as a single agent, but the combination gave a more durable response than either inhibitor alone, albeit not curative.24 PI3K inhibitors are not currently approved for breast cancer, but an FDA-approved inhibitor for mTORC1 does exist. This evidence concerns the gene PIK3CA and breast carcinoma.